Primary pancreatic peripheral T-cell lymphoma: A case report

Table 1 Next-generation sequencing

Gene	Transcript	Sequence changes	Amino acid changes	Functional region	Copy frequency/copy coefficient	Variation level
ERBB4	NM_005235.2	c.3122T>G	p. I1041S	EX25	40.6%	III
STAT3	NM_139276.2	c.1927C>A	p. Q643K	EX21	37.0%	III
CARD11	NM_032415.4	c.2726A>C	p. K909T	EX21	35.2%	III
B2M	NM_004048.2	c.2T>C	p. 0?	EX1	33.8%	III
CXCR4	NM_003467.2	c.1000C>T	p. R334*	EX2	32.8%	II
RELN	NM_005045.3	c.5331T>G	p. I1777M	EX35	32.4%	III
CDKN2B	NM_004936.3	Deficiency		9p21.3	0.3	III
CDKN2A	NM_000077.4	Deficiency		9p21.3	0.2	II

A total of 8 differential genomic variations were obtained by comparing the results of the next-generation sequencing, including ERBB4, STAT3, CARD11, B2M, CXCR4, RELN, CDKN2B and CDKN2A. ERBB4: V-erb-a erythroblastic leukemia viral oncogene homolog 4; STAT3: Signal transducer and activator of transcription 3; CARD11: Caspase Recruitment Domain-containing protein 11; B2M: Beta-2-microglobulin; CXCR4: C-X-C motif chemokine receptor 4; RELN: Reelin; CDKN2B: Cyclin-dependent kinase inhibitor 2B; CDKN2A: Cyclin Dependent Kinase Inhibitor 2A.